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INTRODUCTION
Thyroid nodules are common worldwide, and the prevalence 
of palpable thyroid nodules is 4–7% among adult populations.1,2 
With the increased usage of ultrasound (US) in medical prac-
tice, an increasing number of nonpalpable thyroid nodules 
are detected in 20–67% of the general population.3,4 The ma-
jority of patients with thyroid nodules can be managed over 
time, justifying efforts to select better candidates for thyroidec-
tomy, because approximately 5% of thyroid nodules may have 
malignancy.5,6 Many studies have suggested US criteria that 
could be used to determine malignancy from benign lesions,7,8 
although none of them have shown significant impact on clini-
cal practice, despite the wide acceptance and usefulness of the 
suggested criteria.9
Fine-needle aspiration biopsy (FNAB) is considered to be 
the best diagnostic tool for determining malignant from benign 
nodules. However, FNAB also has a relatively high false-nega-
tive rate, ranging from 0.7 to 21%.10-12 This often leads to a ques-
tion of whether a repeat aspiration should be performed or 
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whether follow-up with US should be performed on suspicious 
thyroid nodules.13,14 
US findings of lymphocytic thyroiditis or Hashimoto’s thy-
roiditis show diffusely coarse and heterogeneous hypoecho-
genicity.15-17 However, lymphocytic thyroiditis can be observed 
as a focal thyroid nodule that appears to be hypoechoic with 
ill-defined margins: an appearance that is indistinguishable 
from that of a malignant nodule (Fig. 1).5,18,19 Therefore, we 
sought to identify clinical and biochemical findings, in addition 
to US features, that could be used to determine focal lympho-
cytic thyroiditis from thyroid malignancy in order to reduce 
the need for repetitive FNABs. 
MATERIALS AND METHODS
Patients
We retrospectively reviewed the medical records of 214 pa-
tients who had thyroid nodules with suspicious features for ma-
lignancy and had undergone US-guided FNAB between Janu-
ary 2005 and December 2010 at Severance Hospital, Seoul, 
Korea. First, we selected 55 patients (mean age, 54.1 years; range, 
26–74 years) who were diagnosed with focal lymphocytic thy-
roiditis (FLT), and 59 patients (mean age, 54.4 years; range, 28–
77 years) diagnosed with adenomatous hyperplasia (AH) by 
two or more repeat FNABs on thyroid nodules with suspicious 
features for malignancy on US. Then we selected 100 papillary 
thyroid cancer (PTC) patients who were diagnosed based on 
surgical pathology after the initial US-guided FNAB, matched 
for sex and age±5 (mean age, 52.5 years; range, 29–82 years) with 
the FLT group or the AH group. We retrospectively reviewed the 
US, cytological, and pathological results of the patients. Hashi-
moto’s thyroiditis is widely known and defined as elevated thy-
rotropin (TSH), as well as antithyroid peroxidase antibody 
(TPO-Ab) positivity and/or antithyroglobulin antibody (Tg-Ab) 
positivity in serum. Only 1 patient with PTC and 2 patients with 
AH received treatment for thyroid diseases with levothyroxine, 
and among 4 patients who had FLT, three were treated with le-
vothyroxine and one with methimazole. 
Laboratory and imaging tests
Thyroid functions were measured by radioimmunoassay using 
T3-CTK (Diasorin SpA, Saluggia, Italy) for T3 and Amerlex-MAB* 
FT4 kit (Trinity Biotech PLC, Wicklow, Ireland) for free T4. Se-
rum TSH level was determined by immunoradiometric assay 
using TSH-CTK-3 kit (Diasorin SpA, Saluggia, Italy). The refer-
ence ranges were 98–180 ng/dL for T3, 0.73–1.95 ng/dL for FT4 
and 0.3–4.0 μIU/mL for TSH. Serum anti-thyroglobulin (Tg-Ab) 
and thyroid peroxidase antibodies (TPO-Ab) were both deter-
mined by the Brahms RIA-Kit (BRAHMS AG, Hennigsdorf, Ger-
many) and the reference ranges were 0–60 IU/mL.
US or US-guided FNAB were performed using a 5–12 MHz 
linear probe (iU22; Philips Medical Systems, Bothell, WA, USA), 
a 7–15 MHz linear probe (HDI 5000; Philips Medical Systems, 
Bothell, WA, USA), or an 8–15 MHz linear probe (Acuson Se-
quoia; Siemens Medical Solutions, Mountain View, CA, USA). 
Key features for “suspicious for malignancy” on US include mi-
crocalcification, irregular or microlobulated margin, hypoecho-
genicity, and taller than wide in shape (i.e., greater anteroposte-
rior dimension than transverse dimension).20,21 “Diffuse thyroid 
disease” (DTD) pattern was defined as diffusely heterogeneous 
hypoechogenicity on sonography.22 US-guided FNAB was per-
formed with a 23-gauge needle attached to a 20-mL disposable 
plastic syringe. Materials obtained from the aspiration biopsy 
were transferred onto glass slides and then placed immediately 
in 95% alcohol for Papanicolaou staining. AH was diagnosed if 
the cytology revealed the presence of colloids and varying 
numbers of follicular cells, and lymphocytic thyroiditis was 
diagnosed if there were follicular cells with scattered back-
ground lymphocytes.5,23
Statistical analysis
All statistical analysis was performed using PASW v. 18.0 for 
Windows (SPSS Inc., Chicago, IL, USA). Comparisons were per-
formed by chi-square test or Fisher’s exact test for categorical 
variables and Student t-test or Mann-Whitney U test for con-
tinuous variables. For multiple comparisons, the ANOVA with 
post hoc Bonferroni procedure was performed. To categorize 
serum TSH levels, we searched the best cut-off point for differ-
Fig. 1. Examples of nodules suspected as malignant on US findings. (A) A 6-mm suspicious nodule (delineated by electronic calipers) was found on the 
right thyroid gland, and PTC was confirmed by surgical pathology. (B) A 7-mm suspicious nodule (delineated by electronic calipers) was found on the 
right thyroid gland and was cytologically confirmed as FLT more than twice by FNAB. The thyroid gland showed diffuse heterogeneous echogenicity, a 
characteristic finding of the DTD pattern of thyroid gland on US. (C) There was a 6-mm suspicious nodule (delineated by electronic calipers) on the left 
thyroid gland, which was cytologically confirmed as AH more than twice by FNAB. PTC, papillary thyroid cancer; FLT, focal lymphocytic thyroiditis; AH, 
adenomatous hyperplasia; FNAB, fine needle aspiration biopsy; DTD pattern, “diffuse thyroid disease” pattern on US; US, ultrasound.
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entiating between PTC and FLT using receiver operating char-
acteristic (ROC) curve analysis, which was 2.50 μIU/mL, with a 
sensitivity of 53% and specificity of 80%. 
To differentiate between FLT and PTC, a logistic regression 
model with the backward stepwise method was used. The sig-
nificant variables identified in an univariate analysis were sub-
sequently entered into a multivariate analysis. In this model, 
the least statistically significant variables were removed one at 
a time until only independent variables with a preset p val-




Baseline characteristics according to FLT, AH, and PTC
Table 1 shows the clinical, biochemical, and US characteris-
tics of the three groups. TSH levels and the frequency of Tg-Ab 
Table 1. Baseline Characteristics According to Cytological Diagnosis 
FLT (n=55) AH (n=59) PTC (n=100) p value
Clinical and biochemical characteristics
Age (yrs) 54.1±11.3 54.4±11.5 52.5±11.4 0.500
Sex (male:female) 4:51 3:56 8:92 0.782
Current medications (%)§ 4 (7.3)* 2 (3.4) 1 (1.0) 0.110
T3 (ng/dL) 151.4±42.8 143.6±26.8 150.2±34.2 0.485
FreeT4 (ng/dL) 1.3±1.1 1.4±1.3 1.55±1.44 0.510
TSH (μIU/mL) 5.5±10.5* 1.8±1.3 1.89±1.31 <0.001
Tg-Ab positive (%) 33 (63.5)‡ 7 (12.3) 16 (16.0) <0.001
TPO-Ab positive (%) 28 (53.8)‡ 6 (10.7) 22 (22.0) <0.001
Largest nodule diameter (mm) 7.5±4.7 10.1±6.5* 8.9±4.9 0.035
Hashimoto’s thyroiditis (%) 28 (50.9)‡ 3 (5.1) 9 (9.0) <0.001
US characteristics
Shape
Taller than wide 28 (50.9) 16 (27.1)‡ 56 (56) 0.002
Wider than tall 27 (49.1) 43 (72.9) 44 (44)
Margin
Well-defined 0 (0.0) 3 (5.1) 1 (1.0) 0.091
Ill-defined 55 (100.0) 56 (94.9) 99 (99.0)
Echogenicity
Marked hypoechoic 5 (9.1) 1 (1.7) 4 (4.0) 0.352
Hypoechoic 45 (81.8) 54 (91.5) 91 (91.0)
Isoechoic 3 (5.5) 1 (1.7) 2 (2.0)
Hyperechoic 2 (3.6) 1 (1.7) 1 (1.0)
Mixed echoic 0 (0.0) 2 (3.4) 2 (2.0)
Calcification
Absence 44 (80.0)†ǁ 29 (49.2) 58 (58.0) 0.005
Micro 2 (3.6) 15 (25.4) 20 (20.0)
Macro 6 (11.0) 7 (11.8) 18 (18.0)
Mixed 2 (3.6) 6 (10.2) 4 (4.0)
Rim 1 (1.8) 2 (3.4) 0 (0.0)
Cystic degeneration
Present 0 (0.0) 0 (0.0) 2 (2.0) 0.316
Absent 55 (100.0) 59 (100.0) 98 (98.0)
DTD pattern
Present 43 (78.2)‡ 6 (10.2) 9 (9.0) <0.001
Absent 12 (21.8) 53 (89.8) 91 (91.0)
FLT, focal lymphocytic thyroiditis; AH, adenomatous hyperplasia; PTC, papillary thyroid cancer; US, ultrasound; DTD pattern, “diffuse thyroid disease” pattern on US; 
TSH, thyrotropin; Tg-Ab, thyroglobulin antibody; TPO-Ab, thyroid peroxidase antibody.
Data are mean±SD or number of patients (%). p value by one-way ANOVA for continuous variables and χ2-test for categorical variables.
*p<0.05, †p<0.01, ‡p<0.001, the comparison of the FLT or AH group with the PTC group, §The portion of the patients treated with levothyroxine or anti-thyroid 
drugs, ǁComparison between the absence and the presence of calcification. 
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and TPO-Ab positivity were significantly different among the 
groups. In terms of US features, the proportions of taller than 
wide shape, calcification of nodules, and DTD pattern on US 
were significantly different among the groups. In comparisons 
between the FLT and PTC groups, as expected, TSH levels 
(p=0.014), Tg-Ab or TPO-Ab positivity (p<0.001), and the pro-
portions of patients taking thyroid medications (p=0.034) and 
having Hashimoto’s thyroiditis (p<0.001) were significantly 
higher in the FLT group than the PTC group. Among US fea-
tures, absence of calcification (p=0.006) and DTD pattern on 
US (p<0.001) were more frequently seen in the FLT group than 
the PTC group. The irregularity of margins, echogenicity, pattern 
of calcifications, and cystic degeneration in nodules did not dif-
fer between the FLT group and the PTC group. However, in 
comparisons between the AH group and the PTC group, nod-
ule size was larger (p=0.029) and the proportion of a taller than 
wide shape of nodules was lower (p<0.001) in the AH group 
than the PTC group. 
 
Comparison between the FLT group and the PTC groups 
according to nodule size
Next, we evaluated whether differences in these variables be-
tween the FLT group and the PTC groups differed according to 
nodule size (<10 mm or ≥10 mm) (Table 2). In terms of thyroid 
Table 2. Clinical, Biochemical, and Sonographic Characteristics of the FLT Group, Compared with the PTC Group, According to Nodule Size
Nodule size <10 mm Nodule size ≥10 mm
FLT (n=45) PTC (n=66) p value FLT (n=10) PTC (n=34) p value
Clinical and biochemical characteristics
Age (yrs) 54.0±11.3 51.6±11.4 0.281 54.9±11.9 54.2±11.3 0.815
Sex (male:female) 4:41 3:63 0.355 10:0 29:5 0.573
Current medications (%)* 3 (6.7) 1 (1.5) 0.153 1 (10.0) 0 (0.0) 0.233
T3 (ng/dL) 156.3±43.5 147.5±35.1 0.284 120.3±20.3 155.5±32.4 0.012
FreeT4 (ng/dL) 1.4±1.2 1.4±1.2 0.978 0.8±0.3 1.8±1.8 0.001
TSH (μIU/mL) 5.7±11.2 1.9±1.4 0.033 4.8±6.7 1.8±1.2 0.044
Tg-Ab positive (%) 27 (64.3) 6 (9.1) <0.001 6 (60.0) 10 (29.4) 0.133
TPO-Ab positive (%) 23 (54.8) 12 (18.2) <0.001 5 (50.0) 10 (29.4) 0.271
Nodule diameter (mm) 6.0±2.0 6.1±1.6 0.858 14.4±0.7 14.4±0.5 0.553
US characteristics
Shape
Taller than wide 25 (55.6) 48 (72.7) 0.061 3 (30.0) 8 (23.5) 0.692
Wider than tall 20 (44.4) 18 (27.3) 7 (70.0) 26 (76.5)
Margin
Well-defined 0 (0.0) 0 (0.0) 1.000 0 (0.0) 1 (2.9) 1.000
Ill-defined 45 (100.0) 66 (100.0) 10 (100.0) 33 (97.1)
Echogenicity
Marked hypoechoic 5 (11.1) 1 (1.5) 0.045 0 (0.0) 3 (8.8) 0.668
Hypoechoic 36 (80.0) 63 (95.9) 9 (90.0) 28 (82.4)
Isoechoic 2 (4.4) 1 (1.5) 1 (10.0) 1 (2.9)
Hyperechoic 2 (4.4) 0 (0.0) 0 (0.0) 1 (2.9)
Mixed echoic 0 (0.0) 1 (1.5) 0 (0.0) 1 (2.9)
Calcification
Present 10 (22.2) 22 (33.3) 0.204 1 (10.0) 20 (58.8) 0.010
Absent 35 (77.8) 44 (66.7) 9 (90.0) 14 (41.2)
Cystic degeneration
Present 0 (0.0) 1 (1.5) 0.407 0 (0.0) 1 (2.9) 1.000
Absent 45 (100.0) 65 (98.5) 10 (100.0) 33 (97.1)
DTD pattern
Present 36 (80.0) 5 (7.6) <0.001 7 (70.0) 4 (11.8) 0.001
Absent 9 (20.0) 61 (92.4) 3 (30.0) 30 (88.2)
PTC, papillary thyroid cancer; FLT, focal lymphocytic thyroiditis; TSH, thyrotropin; Tg-Ab, thyroglobulin antibody; TPO-Ab, thyroid peroxidase antibody; DTD pat-
tern, “diffuse thyroid disease” pattern on US; US, ultrasound. 
Data are mean±SD or number of patients (%). p value by Student’s t-test or Mann-Whitney U test for continuous variables and χ2-test or Fisher exact test for 
categorical variables. 
*The portion of the patients treated with levothyroxine or anti-thyroid drugs.
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cation (OR=12.487, p=0.042) and presence of a DTD pattern on 
US (OR=17.079, p=0.004) remained significant in large FLTs 
≥10 mm. 
Diagnostic predictor model to differentiate FLT from 
PTC
To determine which variables can differentiate FLT from PTC, 
a standard set of predictive measures was calculated for each 
variable or the combination of all three variables of Tg-positivi-
ty, absence of calcification, and presence of a DTD pattern on 
US (Table 5). The presence of the DTD pattern on US showed, 
individually, the best specificity of 91% and positive predictive 
value (PPV) of 83%. In combination analysis of variables, the 
combination of three variables showed the best specificity of 
99% and PPV of 96%, but a low sensitivity of 45%. 
DISCUSSION
Many studies have attempted to investigate a useful indicator of 
thyroid malignancy based on US findings. However, micronod-
ules of lymphocytic thyroiditis can increase in size and be pres-
ent hypoechoic or hyperechoic nodules with ill-defined mar-
gins on US.5,18,19 Therefore, focal thyroiditis is indistinguishable 
from thyroid cancer or lymphoma. These so-called pseudotu-
mors constituted 36% of the nodules of focal thyroiditis detect-
ed by US.5 However, specific US features of focal thyroiditis are 
not well established. 
In the present study, we aimed to identify the characteris-
tics that would clearly distinguish FLT from malignancy, espe-
cially those showing suspicious features on US, and to make a 
diagnostic model for FLT. First, we grouped the patients ac-
cording to diagnostic criteria by following cytologic confirma-
function, TSH levels were elevated in the FLT group, compared 
with the PTC group, regardless of nodules size. However, US 
features were different according to nodule size. In small nod-
ules <10 mm, the echogenicity of nodules (p=0.045) and DTD 
pattern on US (p<0.001) differed significantly between the 
FLT group and the PTC groups. In contrast, among large nod-
ules ≥10 mm, the FLT group showed a higher proportion of 
absence of calcification in thyroid nodules (p=0.010) and a 
DTD pattern on US (p=0.001) than the PTC group.
Univariate and multivariate analysis 
Table 3 shows the odds ratio (OR) with 95% confidence interval 
(CI) for the characteristics more frequently seen in the FLT 
group or the AH group, compared with the PTC group, regardless 
of nodule size. On univariate analysis, the variables associated 
with FLT were TSH >2.50 μIU/mL (OR=4.462, p<0.001) and Tg-
Ab (OR=9.118, p<0.001) and TPO-Ab positivity (OR=4.136, p< 
0.001). Regarding US features, absence of calcification in nodules 
(OR=2.897, p=0.007) and presence of a DTD pattern on US 
(OR=36.231, p<0.001) were associated with FLT rather than PTC. 
On multivariate analysis by the conditional backward method, 
Tg-Ab positivity, absence of calcification in nodules, and pres-
ence of a DTD pattern on US were significant. In contrast, nod-
ules with a taller than wide shape showed significantly lower 
odds in prediction for AH in both univariate (OR=0.292, p= 
0.001) and multivariate (OR=0.288, p=0.001) analysis, suggesting 
that taller than wide shape is associated more with PTC rather 
than AH. 
However, the variables associated with FLT were different ac-
cording to nodule size (Table 4). In small nodules <10 mm, Tg-
Ab positivity (OR=4.985, p=0.027) and presence of a DTD pat-
tern on US (OR=29.265, p<0.001) were significantly associated 
with FLT in multivariate analysis. In contrast, absence of calcifi-
Table 3. Univariate and Multivariate Analysis among Groups
Univariate Multivariate
OR 95% CI p value OR 95% CI p value
FLT vs. PTC
TSH>2.50 μIU/mL 4.462 2.169–9.178 <0.001
Tg-Ab positivity 9.118 4.191–19.841 <0.001 3.036 1.060–8.696 0.039
TPO-Ab positivity 4.136 2.010–8.514 <0.001
Taller than wider 0.815 0.421–1.576 0.543
Absence of calcification 2.897 1.340–6.261 0.007 3.781 1.182–12.097 0.025
Presence of DTD pattern 36.231 14.192–92.500 <0.001 24.519 8.597–69.925 <0.001
AH vs. PTC
TSH>2.50 μIU/mL 0.917 0.404–2.077 0.835
Tg-Ab positivity 0.735 0.283–1.909 0.527
TPO-Ab positivity 0.425 0.161–1.122 0.084 0.427 0.157–1.163 0.096
Taller than wider 0.292 0.146–0.587 0.001 0.288 0.140–0.590 0.001
Absence of calcification 0.700 0.367–1.336 0.280
Presence of DTD pattern 1.145 0.386–3.395 0.808
FLT, focal lymphocytic thyroiditis; PTC, papillary thyroid cancer; AH, adenomatous hyperplasia; TSH, thyrotropin; Tg-Ab, thyroglobulin antibody; TPO-Ab, thyroid 
peroxidase antibody; DTD pattern, “diffuse thyroid disease” pattern on US; OR, odds ratio; CI, confidence interval; US, ultrasound.
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tion of benign nodules, such as lymphocytic thyroiditis or AH 
by two or more FNABs. This is based on the previous reports 
that if the repeat cytological results were both “benign”, the 
risk of malignancy was very low (3.1%).7 Then, we compared 
clinical and biochemical parameters, in addition to US features, 
between FLT or AH and PTC. 
Among US findings, nodules with a taller-than-wide shape 
was the only variable significantly different between AH and 
PTC in this study. This result is also consistent with previous 
studies that a taller-than-wide shape is the best predictor for 
malignancy.21,24 In contrast, it is a task of great significance to 
identify the parameters to differentiate between FLT and PTC 
because many FLTs could have suspicious features on US. We 
found that the combination of three variables, including Tg-Ab 
positivity, absence of calcification in nodules, and presence of 
a DTD pattern on US, was the strongest predictor for FLT. 
However, the sensitivity was only 45%. This may be because 
absence of calcification in nodules had low specificity of 42% 
for FLT. Calcification has been noted in 23.8% of patients with 
focal thyroiditis, which is a greater concern for malignancy.25 In 
the present study, 20% of FLTs had calcification, which could 
indicate malignancy. Therefore, absence or presence of calcifi-
cation in nodules showed relatively low predictive value for 
FLT. 
Lymphocytic thyroiditis shows diffuse heterogeneous hy-
poechogenicity on US, which appeared as a DTD pattern on US 
in our study. This feature is not specific to lymphocytic thyroid-
itis and may be observed in multinodular goiters, autoimmune 
thyroid disease, and subacute thyroiditis.8,15,26 Although a DTD 
pattern on US is a nonspecific presentation for lymphocytic 
thyroiditis, a DTD pattern on US was the strongest predictor 
for FLT, individually, in the present study. It is less clear wheth-
er autoimmunity is the cause or effect of thyroid malignancy. In 
the present study, Tg-Ab positivity showed a significantly great-
er association with FLT than PTC. Meanwhile, TPO-Ab posi-
tivity was also associated with FLT in univariate analysis, but it 
was removed in multivariate analysis. Nevertheless, our results 
do not suggest that only seropositivity or seronegativity of Tg-
Ab is correlated with PTC. 
Recently, guidelines have recommended different manage-
Table 5. Predictor Model of FLT from PTC Based on Individual or Combined Variables
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Tg-Ab positivity 63 84 67 82
Absence of calcification 80 42 43 79
Presence of DTD pattern 79 91 83 88
Tg-Ab positivity and absence of calcification 51 92 78 77
Tg-Ab positivity and presence of DTD pattern 55 96 88 79
Absence of calcification and presence of DTD pattern 65 96 90 83
Tg-Ab positivity, absence of calcification, and presence of DTD pattern 45 99 96 77
FLT, focal lymphocytic thyroiditis; PTC, papillary thyroid cancer; Tg-Ab, thyroglobulin antibody; DTD pattern, “diffuse thyroid disease” pattern on US; PPV, positive 
predictive value; NPV, negative predictive value; US, ultrasound.
Table 4. Univariate and Multivariate Analysis between the FLT Group and the PTC Group According to Nodule Size
Univariate Multivariate
OR 95% CI p value OR 95% CI p value
Nodule size<10 mm
TSH>2.50 μIU/mL 3.883 1.692–8.911 0.001
Tg-Ab positivity 18.99 6.298–51.441 <0.001 4.985 1.201–20.689 0.027
TPO-Ab positivity 5.447 2.278–13.029 <0.001
Taller than wider 0.469 0.211–1.043 0.063 0.337 0.091–1.243 0.102
Absence of calcification 1.750 0.734–4.174 0.207
Presence of DTD pattern 48.800 15.172–156.958 <0.001 29.265 7.788–109.970 <0.001
Nodule size≥10 mm
TSH>2.50 μIU/mL 7.000 1.498–32.720 0.013
Tg-Ab positivity 3.600 0.832–15.572 0.086
TPO-Ab positivity 2.400 0.567–10.155 0.234
Taller than wider 1.393 0.290–6.679 0.679
Absence of calcification 12.857 1.459–113.278 0.021 12.487 1.093–142.673 0.042
Presence of DTD pattern 17.500 3.171–96.575 0.001 17.079 2.464–118.388 0.004
FLT, focal lymphocytic thyroiditis; PTC, papillary thyroid cancer; TSH, thyrotropin; Tg-Ab, thyroglobulin antibody; TPO-Ab, thyroid peroxidase antibody; DTD pat-
tern, “diffuse thyroid disease” pattern on US; OR, odds ratio; CI, confidence interval; US, ultrasound.
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ments based on nodule size.20 Our study also showed different 
predictors for FLT according to nodule size. Based on our results, 
absence or presence of calcification in small nodules <10 mm 
could not predict FLT or malignancy. Tg-Ab positivity and DTD 
pattern on US were only associated with small FLT. 
There are several limitations in this study. First, selection 
bias was inevitable. Second, this study took samples from a 
small number of patients, because we selected patients who 
were diagnosed by two or more repeat FNABs. Third, we did not 
analyze intranodular vascularity, which has been shown to be 
associated with a risk of malignancy.27 
In conclusion, suspicious thyroid nodules with benign cy-
tologic results on initial FNAB could be followed-up with US, 
if there are seropositivity of Tg-Ab, no calcifications in nodules, 
and presence of a DTD pattern on US. Our study provides use-
ful information as a tool for management decision making and 
to reduce the need for repetitive FNABs in thyroid nodules 
with discordant results between benign cytology and suspi-
cious US features. 
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